BTIG downgraded Treace Medical (TMCI) to Neutral from Buy without a price target The company’s implied Q4 outlook was “surprisingly bad,” the analyst tells investors in a research note. The firm says Treace’s “sudden and sizable” guidance reduction to fiscal 2025 estimates suggests a “massive slowdown” in Q4. Physicians are not taking to Lapiplasty as quickly as they are opting for minimally invasive surgery offerings against the backdrop of a weakening macroenvironment, contends BTIG.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Treace Medical downgraded to Underweight from Neutral at JPMorgan
- Treace Medical Concepts Reports Q3 2025 Financial Results
- Treace Medical cuts FY25 revenue view to $211M-$213M from $224M-$230M
- Treace Medical reports Q3 EPS (26c), consensus (27c)
- Treace Medical’s Innovative Foot Correction Study: A Potential Game-Changer?